Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elgene Lim

Showing results (11-20 of 130) with videos related to

Pageof 13
Sort By:
Pharmaceutics|August 26, 2023
Antibody-Drug Conjugates: Ushering in a New Era of Cancer TherapyJoshua Hurwitz, Lucy Roxana Haggstrom, Elgene Lim
Cancers|October 16, 2025
Integrating Molecular Phenotyping into Treatment Algorithms for Advanced Oestrogen Receptor-Positive Breast CancerSarah Childs, Ryoko Semba, Lucy Haggstrom, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 14, 2013
Breast cancer in adolescents and young adults: a review with a focus on biologyJill R Tichy, Elgene Lim, Carey K Anders
Oncology (Williston Park, N.Y.)|September 11, 2012
The natural history of hormone receptor-positive breast cancerElgene Lim, Otto Metzger-Filho, Eric P Winer
Current Oncology Reports|February 11, 2015
Targeting the androgen receptor in breast cancerKeeMing Chia, Megan O'Brien, Myles Brown, et al.
Endocrinology, Diabetes & Metabolism Case Reports|October 22, 2024
Hyperglycemia secondary to phosphatidylinositol-3 kinase (PI3K) inhibitionArunan Sriravindrarajah, Joshua Hurwitz, Elgene Lim, et al.
Drug Design, Development and Therapy|September 9, 2022
Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current StatusTeesha Downton, Fiona Zhou, Davendra Segara, et al.
Asia-Pacific Journal of Clinical Oncology|November 2, 2020
Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancerRichard de Boer, Rina Hui, Elgene Lim, et al.
Asia-Pacific Journal of Clinical Oncology|January 28, 2021
CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of careRina Hui, Richard de Boer, Elgene Lim, et al.
Endocrine-Related Cancer|June 2, 2017
The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapyAndrew M K Law, Elgene Lim, Christopher J Ormandy, et al.
Pageof 13

Showing results (11-20 of 130) with videos related to

Sort By:
Pageof 13
Pharmaceutics|August 26, 2023
Antibody-Drug Conjugates: Ushering in a New Era of Cancer TherapyJoshua Hurwitz, Lucy Roxana Haggstrom, Elgene Lim
Cancers|October 16, 2025
Integrating Molecular Phenotyping into Treatment Algorithms for Advanced Oestrogen Receptor-Positive Breast CancerSarah Childs, Ryoko Semba, Lucy Haggstrom, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 14, 2013
Breast cancer in adolescents and young adults: a review with a focus on biologyJill R Tichy, Elgene Lim, Carey K Anders
Oncology (Williston Park, N.Y.)|September 11, 2012
The natural history of hormone receptor-positive breast cancerElgene Lim, Otto Metzger-Filho, Eric P Winer
Current Oncology Reports|February 11, 2015
Targeting the androgen receptor in breast cancerKeeMing Chia, Megan O'Brien, Myles Brown, et al.
Endocrinology, Diabetes & Metabolism Case Reports|October 22, 2024
Hyperglycemia secondary to phosphatidylinositol-3 kinase (PI3K) inhibitionArunan Sriravindrarajah, Joshua Hurwitz, Elgene Lim, et al.
Drug Design, Development and Therapy|September 9, 2022
Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current StatusTeesha Downton, Fiona Zhou, Davendra Segara, et al.
Asia-Pacific Journal of Clinical Oncology|November 2, 2020
Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancerRichard de Boer, Rina Hui, Elgene Lim, et al.
Asia-Pacific Journal of Clinical Oncology|January 28, 2021
CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of careRina Hui, Richard de Boer, Elgene Lim, et al.
Endocrine-Related Cancer|June 2, 2017
The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapyAndrew M K Law, Elgene Lim, Christopher J Ormandy, et al.
Pageof 13